retatrutide san antonio RETATRUTIDE Efficacy and safety of retatrutide,

2014 Jul;29(4):185196

Aljuaid A, Anwar M

Beyond GLP-1s, AbbVies immunology bet on Skyrizi is paying off: the IL-23 inhibitor posted over 60% growth in both quarters on expanded use in inflammatory bowel disease and ongoing strength in psoriasis

Explaining how some GLP-1 drugs can cause a loss in muscle mass, Andy explained, "I am on a pretty rigorous health journey with Stani, who is like, 'OK, if you're going to do this,' he put me on way heavier weights. "And, by the way, I should mention, I feel privileged to have access to a GLP-1, and I think everybody should, through insurance," he continued

This real-world data is reassuring and suggests that any negative effect, if present, is not common